From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

In this issue, guest editors bring their considerable expertise to this important topic. - Contains 15 practice-oriented topics including new entities and challenges in pediatric hematopathology; IgG4-related lymphadenopathy and lymphoproliferative disorders; the changing landscape of follicular lymphoma: new variants and related entities; breast implant-associated lymphomas; controversies in splenic histiocytic, dendritic, and stromal cell lesions; and more. - Provides in-depth clinical reviews on hematopathology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Critical Care Clinics, guest editors Drs. Lauren R. Sorce and Joy D. Howell bring their considerable expertise to the topic of Pediatric Critical Care. Top experts in the field cover key topics such as point-of-care ultrasound for pediatric critical care providers; transfusion strategies in the 21st century; global pediatric critical care; workforce diversity; and more. - Contains 13 relevant, practice-oriented topics including pediatric redeployment: unique challenges created by COVID-19; ECMO then and now; PCCM in 21st century and beyond; pediatric critical care outcomes; cardiac output monitoring; and more. - Provides in-depth clinical reviews on pediatric critical care, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This premier volume of Advances in Oncology highlights the latest findings and updates within the cancer field each year for the practicing oncologist. Advances in Oncology publishes the most current thinking and recent advances from the voice of a truly distinguished editorial board, including Editor-in-Chief Leonidas C. Platanias, who identify current advances and breakthroughs in the field and invite specialists to contribute original articles on these topics. Topics discussed in this first volume are within the areas of radiation oncology, surgical oncology, medical oncology, gynecologic oncology, pediatric oncology, neuro-oncology, hemato-oncology, uro-oncology, and gastrointestinal oncology. This volume will appeal to all practicing oncologists and will inform and enhance clinical practice.

This issue of Critical Care Clinics, guest edited by Dr. Janice L. Zimmerman, focuses on Toxicology. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: Pharmacokinetic and pharmacodynamic principles for toxicology, Use of extracorporeal techniques in poisonings, Drugs of Abuse, Cardiovascular Drug Toxicity, Anticoagulant and Anti-platelet Drug Toxicity and Psychotropic Agents.

The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.

Up to date and extensively revised to reflect recent advances in the genetics of common diseases, as well as current progress in gene therapy, Medical Genetics, 6th Edition, delivers easy-to-read, highly visual coverage of this rapidly changing field. This accessible, practical text integrates key concepts with clinical practice, highlighted by numerous illustrations, tables, concept summaries, and more – all designed to enhance effective learning and retention of complex material. - Discusses current topics including polygenic risk scores and their potential applications for diabetes, cancer, and heart disease, and the latest sequencing technologies and their clinical application in genetic testing and diagnosis. - Offers a completely updated discussion of genetic testing modalities and applications. - Includes convenient concept summaries, more than 230 photographs, illustrations, and tables, as well as patient/family vignettes that present valuable perspectives on disease and treatment. - Features Clinical Commentary boxes that demonstrate how the hard science of genetics has real applications to everyday patient problems, preparing you for problem-based integrated courses. - Illustrates key concepts with disease examples to demonstrate relevance to medicine. - Provides study questions for self-assessment, as well as 200 additional USMLE-style questions online. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Led by authors from MD Anderson's Stem Cell Transplantation and Cellular Therapy Department, the world's largest and highly respected program at the forefront of rapidly advancing treatments in the field, Manual of Hematopoietic Cell Transplantation and Cellular Therapies is a comprehensive, focused reference covering the latest clinical developments and applications of stem cell transplant and cellular therapies for hematologic malignancies and solid tumors. This cutting-edge title, with a majority contribution from the MD Anderson Cancer Center and leading faculty from other academic institutions, covers breakthrough cell-based therapies for various diseases including lymphoma, multiple myeloma, leukemia, and select solid tumor and autoimmune diseases. This unique, definitive resource is essential for hematologists, fellows in hematology and immunotherapy, mid-level providers, pharmacists, and oncologists who refer patients for cell-based therapies. - Addresses hematologic conditions including leukemia, lymphoma, and myeloma. - Offers guidance on hematopoietic cell transplantation for solid tumors. - Covers basic science principles, clinical aspects, pharmacology, radiation therapy, and disease-specific guidelines, including prevention and management of complications. - Discusses key topics such as hematopoietic cell collection, bone marrow harvesting, umbilical cord blood transplantation, CAR T-cell therapy, and patient/donor selection and preparation of HCT. - Features extensive summary boxes, bulleted content, and algorithms throughout for quick and easy reference. - Offers team-based, clinically-focused coverage from world-renowned leaders in the field.

Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed. - Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy. - Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer. - Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment. - Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care. - Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies – treatments that are being recognized for adverse kidney effects. - Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.